Dual co-stimulation shifts solid tumors from immune silence to active rejection
Solid tumors have long resisted CAR-T therapy for reasons that are now well rehearsed in translational oncology: infused T cells often fade too quickly, suppressive myeloid cells dominate the microenvironment, and malignant cells evade recognition before an adaptive response can mature. A new preclinical strategy attempts to tackle all three problems at once by linking intrinsic T-cell reinforcement to extrinsic immune remodeling.
Investigators built LACO-Stim (lymphocytes-APC co-stimulator), a chimeric co-stimulatory molecule composed of an agonistic anti-CD40 single-chain variable fragment and the CD28 intracellular signaling domain. The design is unusual but mechanistically coherent. One component engages CD40-expressing antigen-presenting cells, while the other delivers CD28 co-stimulation to the T cell that carries it. Co-expressed with a 4-1BB-based CAR, the construct became LACO-CAR-T, a platform intended to do more than recognize tumor antigen. It was built to mobilize the wider immune ecosystem around the tumor as well.
The central result is hard to miss: in vitro, the engineered cells gained anti-tumor potency, and in xenograft and immunocompetent mouse models they produced durable, complete tumor regression in most animals rather than the more familiar pattern of temporary control followed by escape.
CD40 signaling turned antigen-presenting cells into active partners
The logic of the approach rests on a key bottleneck in solid-tumor immunotherapy. CAR-T cells that receive only signal 1 through antigen recognition, or even signal 1 plus a single tonic co-stimulatory pathway, can remain trapped in a biologic environment that actively strips away function. Here, CD40 engagement appears to have been used to wake up antigen-presenting cells inside the tumor and nearby tissue, changing them from passive bystanders into active amplifiers of immunity.
In immunocompetent hosts, LACO-CAR-T activated dendritic cells and shifted tumor macrophages toward an M1-like, antigen-presenting state. Those changes matter because dendritic cells are the cells most capable of priming broader immunity, while M1-like macrophage programs favor antigen presentation and inflammatory signaling that supports rejection rather than tolerance. In a tumor setting that usually suppresses immune visibility, this kind of remodeling can expand the immune response beyond the initial target recognized by the CAR.
The study also described epitope spreading, with endogenous CD8⁺ T-cell responses emerging against tumor neoantigens. This is one of the most important mechanistic observations in the preprint. A therapy that induces epitope spreading is no longer acting as a narrow cytotoxic tool. It is helping the host generate its own additional anti-tumor repertoire, which can be critical when tumors lose the original target or diversify under pressure.
The T-cell state changed, not just the tumor burden
The transcriptional data suggest that the benefit was not limited to better killing. Single-cell transcriptomics and RNA-velocity analysis showed coordinated immune remodeling across compartments. T cells shifted toward a more stem-like, less terminally exhausted phenotype, which is exactly the state associated with persistence and the capacity for renewed expansion after antigen encounter. Terminal exhaustion, by contrast, is a common endpoint for CAR-T cells in hostile solid tumors, where chronic stimulation, hypoxia, nutrient competition, and inhibitory cytokines gradually blunt effector function.
Regulatory T cells declined in frequency and suppressive function. Myeloid cells acquired antigen-presentation programs while excessive inflammatory and suppressive signaling was restrained. In practical terms, the tumor was being pushed away from a closed, immune-excluding niche and toward a more permissive environment in which both infused and endogenous lymphocytes could operate.
The preprint describes this as a de-inflamed and de-suppressed niche rather than merely an armed one. That phrasing fits the biology. A therapy that only increases cytotoxic intensity may still fail if the tumor microenvironment remains structurally hostile. A therapy that also lowers the suppressive set point can convert transient immune pressure into sustained local control.
Why the dual-signal design may matter for solid tumors
The pairing of CD40 activation with CD28 signaling is biologically attractive because it addresses two separate deficits in solid-tumor immunotherapy. CD28 signaling supports early T-cell activation, survival, and expansion, while 4-1BB in the CAR backbone is already associated with improved persistence relative to more activation-heavy alternatives. By adding a second co-stimulatory axis that is tied to antigen-presenting cell activation, the construct may create a feedback loop: the CAR-T cell gains persistence, the antigen-presenting compartment becomes more competent, and the tumor becomes less able to suppress either arm.
This could help explain why the model moved beyond transient tumor suppression to durable regression in most mice. It also helps explain the broader immune readout. If the local microenvironment is reprogrammed, antigen release from dying tumor cells can become immunologically useful instead of being ignored or tolerized. The result is a response that can expand beyond the original CAR target and recruit host immunity against neoantigens that the engineered T cell was never explicitly designed to recognize.
One sentence captures the biologic ambition of the platform: it tries to make the tumor teach the immune system how to keep fighting.
Anti-PD-1 added another layer of control
LACO-Stim also synergized with anti-PD-1 blockade to control tumor growth. That combination is mechanistically plausible. If the engineered cells and the remodeled microenvironment both increase the number and quality of tumor-reactive T cells, then PD-1 inhibition has more functional cells to rescue from checkpoint restraint. In a setting where exhaustion is reduced but not eliminated, checkpoint blockade can still provide an additional release valve.
The synergy suggests that the platform may be compatible with existing immunotherapy strategies rather than competing with them. For solid tumors, that matters. Very few single interventions fully overcome antigen heterogeneity, suppressive myeloid networks, and checkpoint-mediated inhibition at the same time.
Preclinical promise, but still a preprint
The findings come from a preprint and have not been certified by peer review, so the work should be treated as hypothesis-generating rather than practice-changing. The data are nonetheless notable because they connect a defined molecular engineering strategy to several levels of immune effect: T-cell persistence, myeloid reprogramming, dendritic-cell activation, epitope spreading, and checkpoint synergy.
The competing-interest disclosures also frame the interpretation. Several authors are inventors on a patent application related to the work, and some are scientific co-founders or shareholders of UTC Therapeutics Inc. Those disclosures do not diminish the biological observations, but they do make independent replication especially important before any clinical extrapolation.
For now, the preprint defines a clear translational question: can a dual co-stimulatory design preserve the logic of CAR-T engineering while fixing the ecological problem of the solid-tumor niche? The mouse data suggest it can push the answer in that direction, but human tumors will test whether the same immune remodeling can be achieved safely, durably, and with enough consistency to matter at the bedside.